Exhibit 23.2 REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS Board of Directors and Stockholders U.S. Bioscience, Inc. We have audited the consolidated balance sheet of U.S. Bioscience, Inc. as of December 31, 1998 and the related consolidated statements of operations, cash flows and stockholders' equity for the year then ended (not presented separately herein). These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of U.S. Bioscience, Inc. at December 31, 1998, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States. /s/ ERNST & YOUNG LLP Philadelphia, Pennsylvania February 15, 1999
- MEDI Dashboard
- Filings
- News
- Patents
-
10-K Filing
Medimmune (MEDI) Inactive 10-K2000 FY Annual report
Filed: 23 Feb 01, 12:00am